Home>Topics>Funds>PowerShares Dynamic Biotech & Genome

PowerShares Dynamic Biotech & Genome

  1. All
  2. ETF Reports
  1. IBB iShares Nasdaq Biotechnology ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Wed, 16 Apr 2014

    market cap of $9.0 billion. Two other ETF options are PowerShares Dynamic Biotech & Genome PBE (0.63%) and Market Vectors Biotech BBH (0.35 ..... approach to the biotech subsector, investors also can consider PBE , which holds 30 names and has an average market cap of

  2. XBI SPDR S&P Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Wed, 16 Apr 2014

    market cap of $9.1 billion. Two other ETF options are PowerShares Dynamic Biotech & Genome PBE (0.63%) and Market Vectors Biotech BBH (0.35 ..... approach to the biotech subsector, investors also can consider PBE , which holds 30 names and has an average market cap of

  3. FBT First Trust NYSE Arca Biotech Index ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Wed, 16 Apr 2014

    historic risk-adjusted returns. Two other ETF options are PowerShares Dynamic Biotech & Genome PBE (0.63%) and Market Vectors Biotech BBH (0.35 ..... approach to the biotech subsector, investors also can consider PBE , which holds 30 names and has an average market cap of

  4. PBE PowerShares Dynamic Biotech & Genome ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Tue, 21 Aug 2012

    approved to treat ailments such as cancer. PBE 's 0.63% expense ratio exceeds the ..... Alnylam Pharmaceuticals ALNY. Suitability PowerShares Dynamic Biotech & Genome PBE might fit the bill for investors seeking ..... prospects, investors should only consider PBE as a tactical satellite position to a

  5. BBH Market Vectors Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Tue, 17 Apr 2012

    said, as an equal-weight fund, FBT also has greater exposure to small caps, so that means more volatility. Finally, PowerShares Dynamic Biotech & Genome ETF PBE (0.63%) tracks an unorthodox quantitative-active benchmark that selects, ranks and equally weights 30 biotech stocks

  6. FBT First Trust NYSE Arca Biotech Index ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Mon, 1 Mar 2010

    iShares Nasdaq Biotechnology IBB, Biotech HOLDRs BBH, and PowerShares Dynamic Biotech & Genome PBE . Those seeking equal-weight exposure to the biotech industry ..... quantitative-active approach to the subsector, investors might consider PBE , which skews even further down the market-cap spectrum

  7. IBB iShares Nasdaq Biotechnology ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Mon, 1 Mar 2010

    First Trust NYSE Arca Biotechnology FBT (0.60%), PowerShares Dynamic Biotech & Genome PBE (0.60%), and Biotech HOLDRs BBH. Both XBI and FBT offer ..... quantitative-active approach to the subsector, investors might consider PBE , which skews even further down the market-cap spectrum

  8. PBE PowerShares Dynamic Biotech & Genome ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Mon, 1 Mar 2010

    roughly 15%, 27%, and 58% of total assets, respectively. PBE 's holdings-weighted average market cap of roughly $2 ..... significantly smaller than other rival biotech funds. Suitability PowerShares Dynamic Biotech & Genome PBE might fit the bill for investors seeking to add some biotechnology

  9. XBI SPDR S&P Biotech ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Wed, 17 Feb 2010

    Trust NYSE Arca Biotech Index FBT, Biotech HOLDRs BBH, and PowerShares Dynamic Biotech & Genome PBE . Those seeking equal-weight exposure to the biotech industry ..... quantitative-active approach to the subsector, investors might consider PBE , which skews even further down the market-cap spectrum

Content Partners